Paul H Klingenstein
CIK 935463 · last filed 2021-06-11
Paul H Klingenstein is a corporate insider who has filed 32 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for CLVS, was dated Jun 11, 2021. Across all open-market trades the lifetime net is +$12.4M, making them a net buyer over the disclosed history. 4 SEC filings were submitted jointly with ACCEL INTERNET FUND III ASSOCIATES LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CLVS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
C/O ACCEL PARTNERS
PALO ALTO, CA 94301
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Clovis Oncology, Inc. (CLVS) Delisted | Director | 72,082 | $0.08 | $5.9K | $5.19M | 11 | 2021-06-11 |
| Histogen Inc. (CNAT) Delisted | Director | 2,905 | — | — | $1.18M | 2 | 2014-02-25 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Director | 382,976 | $10.19 | $3.90M | $1.50M | 5 | 2013-06-07 |
| ReShape Weightloss Inc. (ETRM) Delisted | Director | 31,157 | — | — | $4.54M | 14 | 2013-05-10 |
Recent Filings
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-11 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-05 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-07-31 | Clovis Oncology, Inc. (CLVS) Delisted | Exer (M) | +25,862 | $7.5K | EDGAR |
| 2019-06-07 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-10-15 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-08 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-10 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-15 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-02-25 | Histogen Inc. (CNAT) Delisted | Other (J) | −1,284,752 | $0 | EDGAR |
| 2013-08-01 | Histogen Inc. (CNAT) Delisted | Mixed | +2,218,758 | $1.30M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.